journal
Journals Therapeutic Advances in Medica...

Therapeutic Advances in Medical Oncology

https://read.qxmd.com/read/36950276/direct-gdp-kras-g12c-inhibitors-and-mechanisms-of-resistance-the-tip-of-the-iceberg
#1
REVIEW
Joshua C Rosen, Adrian Sacher, Ming-Sound Tsao
Kirsten rat sarcoma viral oncogene homolog mutations are observed in 25% of lung adenocarcinoma and 40% of these are G12C mutations. Historically, no approved targeted agents were available for patients with any KRAS mutation, and response rates to standard-of-care therapies were suboptimal. Newly developed inhibitors directed toward KRASG12C have been successful in clinical trials with overall response rates ranging between 32% and 46%, and two FDA approvals were granted in May 2021 and December 2022 as second-line or later monotherapies...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36950275/efficacy-of-immunotherapy-in-oncogene-driven-non-small-cell-lung-cancer
#2
REVIEW
Natalie I Vokes, Kelsey Pan, Xiuning Le
For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven approvals within the last 5 years. This accelerated drug development has expanded the reach of targeted therapies, and it may soon be that a majority of patients with lung adenocarcinoma will be eligible for a targeted therapy during their treatment course. With these emerging therapeutic options, it is important to understand the existing data on immune checkpoint inhibitors (ICIs), along with their efficacy and safety for each oncogene-driven lung cancer, to best guide the selection and sequencing of various therapeutic options...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36950274/a-systematic-review-of-therapeutic-strategies-in-gastroenteropancreatic-grade-3-neuroendocrine-tumors
#3
REVIEW
Mauro D Donadio, Ângelo B Brito, Rachel P Riechelmann
BACKGROUND: Gastroenteropancreatic (GEP) neuroendocrine neoplasms with Ki-67 > 20% were subdivided in the most recent 2019 World Health Organization histopathological classification into grade 3 (G3) neuroendocrine tumors (NETs), described as well-differentiated tumors, and neuroendocrine carcinomas, which are described as poorly differentiated tumors. This classification met the demand noted for different prognoses between these subgroups, prompting the need for treatment recommendations for well-differentiated G3 tumors...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36950273/time-for-a-lead-time-definition-author-response-to-why-the-length-of-recurrence-free-survival-or-lead-times-can-be-misleading-comment-on-callesen-lb-takacova-t-hamfjord-j-et-al-circulating-dna-in-patients-undergoing-loco-regional-treatment-of-colorectal-cancer
#4
COMMENT
https://read.qxmd.com/read/36950272/oligometastatic-breast-cancer-and-metastasis-directed-treatment-an-aggressive-multimodal-approach-to-reach-the-cure
#5
REVIEW
Filippo Merloni, Michela Palleschi, Chiara Casadei, Antonino Romeo, Annalisa Curcio, Roberto Casadei, Franco Stella, Giorgio Ercolani, Caterina Gianni, Marianna Sirico, Simona Cima, Samanta Sarti, Lorenzo Cecconetto, Giandomenico Di Menna, Ugo De Giorgi
Metastatic breast cancer (BC) is considered an incurable disease and is usually treated with palliative intent. However, about 50% of metastatic BCs present with only a few metastatic lesions and are characterized by longer overall survival. These patients, defined as oligometastatic, could benefit from a multimodal approach, which combines systemic therapy with metastasis-directed treatment (stereotactic ablative therapy or surgery). The current definition of oligometastatic seems incomplete since it is based only on imaging findings and does not include biological features, and the majority of relevant data supporting this strategy comes from retrospective or non-randomized studies...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36950271/established-and-new-horizons-in-radiotherapy-for-breast-cancer
#6
REVIEW
Trudy C Wu, Susan A McCloskey
Modern advances in diagnostics, surgery, systemic therapies, and radiotherapy (RT) have drastically revolutionized treatment strategies for breast cancer. This review outlines current and evolving treatment paradigms for RT in the breast-conserving therapy and post-mastectomy setting. In early-stage breast cancer, there is active investigation in expanding eligibility for omission of RT in women with more biologically favorable tumors and growing options to effectively irradiate less breast tissue and shorten RT treatment courses...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36950270/a-rapidly-evolving-landscape-immune-checkpoint-inhibitors-in-pretreated-metastatic-endometrial-cancer
#7
REVIEW
Anna V Tinker, Neesha C Dhani, Prafull Ghatage, Deanna McLeod, Vanessa Samouëlian, Stephen A Welch, Alon D Altman
BACKGROUND AND OBJECTIVES: Endometrial cancer is a common malignancy and recurrences can be fatal. Although platinum-pretreated endometrial tumors are commonly treated with anthracyclines and taxanes, there is no current standard of care. Both immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have been extensively assessed in this setting, including tumors selected for DNA mismatch repair (MMR)/microsatellite instability (MSI) and programmed death-ligand 1 expression status...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36936200/circulating-tumour-dna-in-the-evolving-treatment-landscape-of-locally-advanced-rectal-cancer-where-does-it-fit-in
#8
REVIEW
Oliver Piercey, Jeanne Tie
The management of locally advanced rectal cancer (LARC) requires multimodality treatment, typically with neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision. However, the treatment landscape is rapidly evolving with total neoadjuvant therapy and non-operative management for selected patients emerging as other novel treatment approaches. With so many treatment options, there is a need for biomarkers to direct a more personalised treatment strategy for patients with LARC. In this review, we summarise the available data regarding the use of circulating tumour DNA (ctDNA) in patients with LARC, as both a marker of treatment response to neoadjuvant therapy and as a marker of minimal residual disease (MRD) after patients have completed definitive local treatment...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36936199/development-of-a-nomogram-for-predicting-pathological-complete-response-in-luminal-breast-cancer-patients-following-neoadjuvant-chemotherapy
#9
JOURNAL ARTICLE
Giovanna Garufi, Luisa Carbognin, Isabella Sperduti, Federica Miglietta, Maria Vittoria Dieci, Roberta Mazzeo, Armando Orlandi, Lorenzo Gerratana, Antonella Palazzo, Alessandra Fabi, Ida Paris, Antonio Franco, Gianluca Franceschini, Elena Fiorio, Sara Pilotto, Valentina Guarneri, Fabio Puglisi, Pierfranco Conte, Michele Milella, Giovanni Scambia, Giampaolo Tortora, Emilio Bria
BACKGROUND: Given the low chance of response to neoadjuvant chemotherapy (NACT) in luminal breast cancer (LBC), the identification of predictive factors of pathological complete response (pCR) represents a challenge. A multicenter retrospective analysis was performed to develop and validate a predictive nomogram for pCR, based on pre-treatment clinicopathological features. METHODS: Clinicopathological data from stage I-III LBC patients undergone NACT and surgery were retrospectively collected...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36936198/diagnostic-value-of-whole-mount-crypt-analysis-of-ileal-biopsy-specimens-for-the-patients-with-familial-small-intestinal-neuroendocrine-tumors
#10
JOURNAL ARTICLE
Yoshitatsu Sei, Joanne Forbes, Ben Da, Ehsan Chitsaz, Jianying Feng, Xilin Zhao, Marybeth S Hughes, Stephen A Wank
BACKGROUND AND AIMS: Early-stage small intestinal neuroendocrine tumors (SI-NETs) are generally asymptomatic and difficult to diagnose. As a result, patients often present with late-stage incurable disease. SI-NETs originate from enterochromaffin (EC) cells, which develop enteroendocrine cell (EEC) clusters consisting of a subset of EC cells at the crypt bottom at an early stage of tumor progression. In a familial form of SI-NET, EEC clusters arise in a multifocal and polyclonal fashion...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36895853/treatment-strategies-based-on-different-oligoprogressive-patterns-after-immunotherapy-failure-in-metastatic-nsclc
#11
JOURNAL ARTICLE
Wendi Xuzhang, Huayan Huang, Yongfeng Yu, Lan Shen, Ziming Li, Shun Lu
BACKGROUND: Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns. METHODS: Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression with a history of polymetastatic disease), de-novo polyprogression (DNP, polyprogression with a history of oligometastatic disease), and repeat polyprogression (REP, polyprogression with a history of polymetastatic disease)...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36895852/clinical-outcomes-of-volume-of-disease-on-patients-receiving-enzalutamide-versus-abiraterone-acetate-plus-prednisone-as-first-line-therapy-for-metastatic-castration-resistant-prostate-cancer
#12
JOURNAL ARTICLE
Pier Vitale Nuzzo, Francesco Ravera, Calogero Saieva, Elisa Zanardi, Giuseppe Fotia, Andrea Malgeri, Sabrina Rossetti, Loana Bueno Valença, Thiago Martins Oliveira, Charles Vauchier, Ricardo Pereira Mestre, Mikol Modesti, Anna Patrikidou, Sandro Pignata, Giuseppe Procopio, Giuseppe Fornarini, Ugo De Giorgi, Antonio Russo, Edoardo Francini
BACKGROUND: Androgen receptor signaling inhibitors (ARSis) abiraterone acetate (AA) plus prednisone and enzalutamide (Enza), are currently the most administered first-line treatments for metastatic castration-resistant prostate cancer (mCRPC). AA and Enza have shown similar overall survival (OS) benefits and there is no consensus upon the best option for mCRPC first-line treatment. Volume of disease may represent a useful biomarker to predict response to therapy in such patients. OBJECTIVES: In this study, we seek to evaluate the impact of volume of disease on patients treated with first-line AA versus Enza for mCRPC...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36895851/status-of-psma-targeted-radioligand-therapy-in-prostate-cancer-current-data-and-future-trials
#13
REVIEW
Albert Jang, Ayse T Kendi, Oliver Sartor
Metastatic prostate cancer continues to be an incurable disease. Despite all the novel therapies approved in the past two decades, overall patient outcomes remain relatively poor, and these patients die on a regular basis. Clearly, improvements in current therapies are needed. Prostate-specific membrane antigen (PSMA) is a target for prostate cancer given its increased expression on the surface of the prostate cancer cells. PSMA small molecule binders include PSMA-617 and PSMA-I&T and monoclonal antibodies such as J591...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36895850/the-agamenon-seom-model-for-prediction-of-survival-in-patients-with-advanced-her2-positive-oesophagogastric-adenocarcinoma-receiving-first-line-trastuzumab-based-therapy
#14
JOURNAL ARTICLE
Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor, Javier Gallego
BACKGROUND: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab. METHODS: Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36895849/circulating-tumor-dna-toward-evolving-the-clinical-paradigm-of-pancreatic-ductal-adenocarcinoma
#15
REVIEW
James T Topham, Daniel J Renouf, David F Schaeffer
Over a decade of sequencing-based genomics research has unveiled a diverse somatic mutation landscape across patients with pancreatic ductal adenocarcinoma (PDAC), and the identification of druggable mutations has aligned with the development of novel targeted therapeutics. However, despite these advances, direct translation of years of PDAC genomics research into the clinical care of patients remains a critical and unmet need. Technologies that enabled the initial mapping of the PDAC mutation landscape, namely whole-genome and transcriptome sequencing, remain overly expensive in terms of both time and financial resources...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36891484/efficacy-analysis-of-neoadjuvant-chemotherapy-with-or-without-anthracyclines-in-female-patients-with-her2-positive-breast-cancer-in-china-a-nationwide-multicenter-10-year-retrospective-study-csbrs-012
#16
JOURNAL ARTICLE
Heyan Chen, Amina Maimaitiaili, Zhenzhen Liu, Rui Ling, Yi Zhao, Hongjian Yang, Yunjiang Liu, Ke Liu, Jianguo Zhang, Dahua Mao, Zhigang Yu, Yinhua Liu, Peifen Fu, Jiandong Wang, Hongchuan Jiang, Zuowei Zhao, Xingsong Tian, Zhongwei Cao, Kejin Wu, Ailin Song, Feng Jin, Jianjun He, Zhimin Fan, Huimin Zhang
BACKGROUND: In the era of targeted therapy, whether patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer are exempted from anthracycline usage in the neoadjuvant setting is controversial. OBJECTIVES: Our objective was to retrospectively analyze the differences in pathological complete remission (pCR) rates between the anthracycline group and the nonanthracycline group. DESIGN: The CSBrS-012 study (2010-2020) included female primary breast cancer patients with neoadjuvant chemotherapy (NAC) who underwent standard breast and axillary surgery post-NAC...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36872949/patient-outcomes-following-a-response-biomarker-guided-approach-to-treatment-using-177lu-psma-i-t-in-men-with-metastatic-castrate-resistant-prostate-cancer-re-spect
#17
JOURNAL ARTICLE
Louise Emmett, Nikeith John, Sarennya Pathmanandavel, William Counter, Maria Ayers, Shikha Sharma, Shikha Agrawal, Aron Poole, Elizabeth Hovey, Ganes Pranavan, Craig Gedye, Girish Mallesara, Alex Guminski, Adrian Lee, Martin R Stockler, Adam Hickey, Peter Eu, Anthony M Joshua, Megan Crumbaker, Andrew Nguyen
BACKGROUND: 177 LuPSMA is an effective treatment in metastatic castrate-resistant prostate cancer with trials adopting a standardised dose interval. Adjusting treatment intervals utilising early response biomarkers may improve patient outcomes. OBJECTIVE: This study evaluated progression-free survival (PFS) and overall survival (OS) based on treatment interval adjustment utilising 177 LuPSMA 24-h SPECT/CT (177 Lu-SPECT) and early prostate-specific antigen (PSA) response...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36872948/the-association-between-her2-low-expression-and-prognosis-of-breast-cancer-a-systematic-review-and-meta-analysis
#18
JOURNAL ARTICLE
Yuyao Tang, Guoshuang Shen, Yuanfang Xin, Zhoujuan Li, Yonghui Zheng, Miaozhou Wang, Zhen Liu, Yi Zhao, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao
BACKGROUND: The use of antibody-drug conjugates for the treatment of advanced-stage human epidermal growth factor receptor 2 (HER2)-low expression in breast cancer (BC) has shown prominent curative effects, which has led to increased academic interest. However, the role of HER2-low expression in the prognosis of BC remains controversial. METHODS: We conducted a systematic search of the PubMed, Embase, and Cochrane library databases and several oncology conferences until 20 September 2022...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36872947/fighting-resistance-post-parp-inhibitor-treatment-strategies-in-ovarian-cancer
#19
REVIEW
Ana C Veneziani, Clare Scott, Matthew J Wakefield, Anna V Tinker, Stephanie Lheureux
Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/36872946/potent-molecular-targeted-therapies-for-advanced-esophageal-squamous-cell-carcinoma
#20
REVIEW
Akira Ooki, Hiroki Osumi, Keisho Chin, Masayuki Watanabe, Kensei Yamaguchi
Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemotherapy, including cytotoxic agents and immune checkpoint inhibitors, is the main therapeutic option for recurrent or metastatic ESCC patients, the clinical benefits are limited with poor prognosis. Personalized molecular-targeted therapies have been hampered due to the lack of robust treatment efficacy in clinical trials...
2023: Therapeutic Advances in Medical Oncology
journal
journal
42443
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.